1. Home
  2. GTLB vs DFTX Comparison

GTLB vs DFTX Comparison

Compare GTLB & DFTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo GitLab Inc.

GTLB

GitLab Inc.

N/A

Current Price

$41.67

Market Cap

5.5B

Sector

Technology

ML Signal

N/A

Logo Definium Therapeutics Inc. Common Shares

DFTX

Definium Therapeutics Inc. Common Shares

N/A

Current Price

$44.91

Market Cap

5.9B

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
GTLB
DFTX
Founded
2011
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Sector
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
5.9B
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
GTLB
DFTX
Price
$41.67
$44.91
Analyst Decision
Buy
Strong Buy
Analyst Count
27
8
Target Price
$37.17
$38.50
AVG Volume (30 Days)
4.1M
2.1M
Earning Date
06-09-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$955,224,000.00
N/A
Revenue This Year
$18.72
N/A
Revenue Next Year
$16.05
N/A
P/E Ratio
N/A
N/A
Revenue Growth
25.81
N/A
52 Week Low
$18.73
$14.62
52 Week High
$52.38
$49.70

Technical Indicators

Market Signals
Indicator
GTLB
DFTX
Relative Strength Index (RSI) 61.70 55.05
Support Level $36.50 $40.46
Resistance Level $43.00 $45.42
Average True Range (ATR) 1.97 2.76
MACD 0.07 -0.07
Stochastic Oscillator 74.65 49.56

Price Performance

Historical Comparison
GTLB
DFTX

About GTLB GitLab Inc.

GitLab Inc operates on an all-remote model. GitLab is a complete DevSecOps platform delivered as a single application. It operates in two competitive landscapes: DevOps point solutions and DevOps platforms. In terms of point solutions that are stitched together, GitLab's offering is substantially different in that it is one platform, one codebase, one interface, and a unified data model that spans the entire DevSecOps lifecycle. DevOps platforms, the principal competitor is Microsoft Corporation, following their acquisition of GitHub. GitLab is offered on both self-managed and software-as-a-service (SaaS) models. It is located in the United States, Europe, & the Asia Pacific. It focused on accelerating innovation & broadening the distribution of its platform to companies across the world.

About DFTX Definium Therapeutics Inc. Common Shares

Definium Therapeutics Inc is developing inventive, next-generation therapeutics intended to solve the underlying causes of psychiatric and neurological disorders and offer patients long-term remission rather than transient symptom reduction. Its late-stage pipeline includes four Phase 3 trials-two each for GAD and MDD-anchored by its candidate, DT120 ODT, which has received FDA Breakthrough Therapy Designation for GAD. In parallel, the Company is advancing its commercial and operational readiness to support a care model and prepare for the potential launch of DT120 ODT, if approved and marketed. The company operates in one reportable segment relating to the research and development of the company's neurological drug development platform.

Share on Social Networks: